Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Validation of warfarin pharmacogenetic algorithms in clinical practice.

Marin-Leblanc M, Perreault S, Bahroun I, Lapointe M, Mongrain I, Provost S, Turgeon J, Talajic M, Brugada R, Phillips M, Tardif JC, Dubé MP.

Pharmacogenomics. 2012 Jan;13(1):21-9. doi: 10.2217/pgs.11.120.

PMID:
22176621
2.

Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.

Bazan NS, Sabry NA, Rizk A, Mokhtar S, Badary O.

Int J Clin Pharm. 2012 Dec;34(6):837-44. doi: 10.1007/s11096-012-9678-3. Epub 2012 Jul 27.

PMID:
22851439
3.

Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.

Cho HJ, On YK, Bang OY, Kim JW, Huh W, Ko JW, Kim JS, Lee SY.

Clin Ther. 2011 Oct;33(10):1371-80. doi: 10.1016/j.clinthera.2011.09.004. Epub 2011 Oct 6.

PMID:
21981797
4.

Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic.

Shaw PB, Donovan JL, Tran MT, Lemon SC, Burgwinkle P, Gore J.

J Thromb Thrombolysis. 2010 Aug;30(2):220-5. doi: 10.1007/s11239-010-0459-3.

PMID:
20204461
5.

A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.

Wei M, Ye F, Xie D, Zhu Y, Zhu J, Tao Y, Yu F.

Thromb Haemost. 2012 Jun;107(6):1083-91. doi: 10.1160/TH11-12-0848. Epub 2012 Apr 26.

PMID:
22534826
6.

Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.

Schwartz JB, Kane L, Moore K, Wu AH.

J Am Med Dir Assoc. 2011 Nov;12(9):633-8. doi: 10.1016/j.jamda.2010.12.006. Epub 2011 Jan 26.

PMID:
21450231
7.

VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study.

Zambon CF, Pengo V, Padrini R, Basso D, Schiavon S, Fogar P, Nisi A, Frigo AC, Moz S, Pelloso M, Plebani M.

Pharmacogenomics. 2011 Jan;12(1):15-25. doi: 10.2217/pgs.10.162.

PMID:
21174619
8.

Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation.

Xu Q, Xu B, Zhang Y, Yang J, Gao L, Zhang Y, Wang H, Lu C, Zhao Y, Yin T.

Thromb Haemost. 2012 Dec;108(6):1132-40. doi: 10.1160/TH12-05-0362. Epub 2012 Sep 26.

PMID:
23015069
9.

Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients.

Pathare A, Al Khabori M, Alkindi S, Al Zadjali S, Misquith R, Khan H, Lapoumeroulie C, Paldi A, Krishnamoorthy R.

J Hum Genet. 2012 Oct;57(10):665-9. doi: 10.1038/jhg.2012.94. Epub 2012 Aug 2.

PMID:
22854539
10.

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.

Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F.

Blood. 2005 Oct 1;106(7):2329-33. Epub 2005 Jun 9.

11.

Accuracy assessment of pharmacogenetic algorithms for warfarin dose prediction in Chinese patients.

Lei X, Guo Y, Sun J, Zhou H, Liu Y, Liang P, Yan Z.

Am J Hematol. 2012 May;87(5):541-4. doi: 10.1002/ajh.23151. Epub 2012 Mar 28.

12.

CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.

Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ.

Pharmacogenomics. 2009 Aug;10(8):1243-55. doi: 10.2217/pgs.09.71.

13.

The Creating an Optimal Warfarin Nomogram (CROWN) Study.

Perlstein TS, Goldhaber SZ, Nelson K, Joshi V, Morgan TV, Lesko LJ, Lee JY, Gobburu J, Schoenfeld D, Kucherlapati R, Freeman MW, Creager MA.

Thromb Haemost. 2012 Jan;107(1):59-68. doi: 10.1160/TH11-08-0568. Epub 2011 Nov 24.

14.

Estimation of the warfarin dose with clinical and pharmacogenetic data.

International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA.

N Engl J Med. 2009 Feb 19;360(8):753-64. doi: 10.1056/NEJMoa0809329. Erratum in: N Engl J Med. 2009 Oct 15;361(16):1613. Dosage error in article text.

15.

A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms.

Cini M, Legnani C, Cosmi B, Guazzaloca G, Valdrè L, Frascaro M, Palareti G.

Eur J Clin Pharmacol. 2012 Aug;68(8):1167-74. doi: 10.1007/s00228-012-1226-5. Epub 2012 Feb 19.

PMID:
22349464
16.

Evaluation of pharmacogenetic algorithm for warfarin dose requirements in Japanese patients.

Takeuchi F, Kashida M, Okazaki O, Tanaka Y, Fukuda S, Kashima T, Hosaka S, Hiroe M, Kimura S, Kato N.

Circ J. 2010 May;74(5):977-82. Epub 2010 Mar 26.

17.

Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.

Wu AH, Wang P, Smith A, Haller C, Drake K, Linder M, Valdes R Jr.

Pharmacogenomics. 2008 Feb;9(2):169-78. doi: 10.2217/14622416.9.2.169.

PMID:
18370846
18.

Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.

Teh LK, Langmia IM, Fazleen Haslinda MH, Ngow HA, Roziah MJ, Harun R, Zakaria ZA, Salleh MZ.

J Clin Pharm Ther. 2012 Apr;37(2):232-6. doi: 10.1111/j.1365-2710.2011.01262.x. Epub 2011 Apr 20.

PMID:
21507031
19.

Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A.

Gao L, He L, Luo J, Xu B, Yang J, Zhang YX, Yang T, Li K, Tian JW, Wang HJ, Zhao YS, Lu CY, Zhang WZ, Yin T.

Chin Med J (Engl). 2011 Sep;124(17):2767-70.

PMID:
22040439
20.

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.

Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF; Couma-Gen Investigators.

Circulation. 2007 Nov 27;116(22):2563-70. Epub 2007 Nov 7.

Supplemental Content

Support Center